Clinical Trial Update: Recombinant Factor VIIa in Acute Intracerebral Haemorrhage [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating recombinant factor VIIa for acute intracerebral hemorrhage has completed; the study was sponsored by Novo Nordisk A/S.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Bleeding Disorder
• Intracerebral Hemorrhage

Drugs mentioned

• NovoSeven (recombinant coagulation factor VIIa)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Acquired Bleeding Disorder, Intracerebral Haemorrhage | Phase 2 | Status: COMPLETED